Journal of Clinical Endocrinology & Metabolism, Vol 71, 127-132, Copyright © 1990 by Endocrine Society

ARTICLES

Changes in vitamin D metabolism during natural and medical menopause

D Hartwell, BJ Riis and C Christiansen
Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.

Thirty-nine women were studied longitudinally for 3 yr, during which period 10 women passed a natural menopause. Vitamin D metabolites were determined every 3 months in these 10 women. The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months. No changes were seen in 1,25-dihydroxyvitamin D [1,25-(OH)2D], vitamin D- binding protein, or the free index of 1,25-(OH)2D during the natural menopause. A small increase was found in 25-hydroxyvitamin D [25OHD] and 24,25-(OH)2D3 after correction for seasonal variation. All three nafarelin groups had a significantly decreased free index of 1,25- (OH)2D, which returned to the baseline value on withdrawal of the treatment. Serum 25OHD and 24,25-(OH)2D3 were increased at 6 months and thereafter decreased to baseline values. These changes were still visible after correction for seasonal variation. Vitamin D-binding protein showed a small transient increase in the nafarelin plus NET group, but was unchanged in the other two groups. The 24-h urinary excretion of calcium increased significantly in the groups receiving nafarelin alone, whereas it remained unchanged in the nafarelin plus NET group. We conclude that detectable changes in 1,25-(OH)2D do not occur in natural menopause. Treatment with LHRH agonists produces a significant decrease in serum 1,25-(OH)2D, which does not seem to be dependent on increased bone resorption. This suggests that LHRH agonists may induce a change in other pituitary hormones involved in vitamin D regulation.

This article has been cited by other articles:

				P Vigano, D Lattuada, S Mangioni, L Ermellino, M Vignali, E Caporizzo, P Panina-Bordignon, M Besozzi, and A M Di Blasio Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J. Mol. Endocrinol., June 1, 2006; 36(3): 415 - 424. [Abstract] [Full Text] [PDF]

				R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein and D. A. Schoenfeld Effects of Gonadal Suppression on the Regulation of Parathyroid Hormone and 1,25-Dihydroxyvitamin D Secretion in Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2151 - 2156. [Abstract] [Full Text]